Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth or by blocking blood flow to the tumor. Stereotactic
radiosurgery (SRS) may be able to send x-rays directly to the tumor and cause less damage to
normal tissue. Giving sorafenib tosylate together with SRS may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and the best dose of sorafenib
tosylate when given together with SRS in treating patients with brain metastases